Allspring Global Investments Holdings LLC bought a new position in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 31,443 shares of the company’s stock, valued at approximately $78,000. Allspring Global Investments Holdings LLC owned about 0.06% of G1 Therapeutics at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in shares of G1 Therapeutics by 5.6% in the 1st quarter. JPMorgan Chase & Co. now owns 2,149,526 shares of the company’s stock valued at $5,761,000 after acquiring an additional 113,904 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of G1 Therapeutics by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,686,453 shares of the company’s stock valued at $21,063,000 after acquiring an additional 65,952 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of G1 Therapeutics by 42.6% in the 4th quarter. Millennium Management LLC now owns 1,671,859 shares of the company’s stock valued at $9,078,000 after acquiring an additional 499,363 shares during the last quarter. State Street Corp boosted its holdings in shares of G1 Therapeutics by 1,038.1% in the 3rd quarter. State Street Corp now owns 1,618,381 shares of the company’s stock valued at $20,214,000 after acquiring an additional 1,476,175 shares during the last quarter. Finally, BlackRock Inc. boosted its holdings in shares of G1 Therapeutics by 11.0% in the 3rd quarter. BlackRock Inc. now owns 1,519,657 shares of the company’s stock valued at $18,980,000 after acquiring an additional 150,376 shares during the last quarter. Hedge funds and other institutional investors own 30.04% of the company’s stock.
G1 Therapeutics Stock Performance
GTHX opened at $1.29 on Thursday. The company has a quick ratio of 3.68, a current ratio of 4.14 and a debt-to-equity ratio of 0.89. The company has a market cap of $66.75 million, a price-to-earnings ratio of -0.75 and a beta of 1.87. G1 Therapeutics, Inc. has a 52-week low of $1.08 and a 52-week high of $11.78. The firm’s fifty day simple moving average is $1.52 and its two-hundred day simple moving average is $2.23.
Analyst Upgrades and Downgrades
Several research firms have recently commented on GTHX. JPMorgan Chase & Co. downgraded shares of G1 Therapeutics from a “neutral” rating to an “underweight” rating in a report on Friday, October 6th. Needham & Company LLC decreased their target price on shares of G1 Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, August 2nd. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of G1 Therapeutics in a research note on Thursday, August 3rd. Finally, Wedbush reiterated an “outperform” rating and issued a $5.00 target price on shares of G1 Therapeutics in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.80.
Check Out Our Latest Research Report on G1 Therapeutics
About G1 Therapeutics
G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
See Also
- Five stocks we like better than G1 Therapeutics
- How to Effectively Use the MarketBeat Ratings Screener
- Dollar Tree Won’t Be Trading At a Discount For Much Longer
- Stock Market Upgrades: What Are They?
- ASML Holding is a Great Buy but at a Cheaper Price
- Find and Profitably Trade Stocks at 52-Week Lows
- Oversold and Overextended, Abbott Laboratories is a Great Buy
Want to see what other hedge funds are holding GTHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for G1 Therapeutics, Inc. (NASDAQ:GTHX – Free Report).
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
